Search details
1.
DFV890: a new oral NLRP3 inhibitor-tested in an early phase 2a randomised clinical trial in patients with COVID-19 pneumonia and impaired respiratory function.
Infection
; 51(3): 641-654, 2023 Jun.
Article
in English
| MEDLINE | ID: mdl-36104613
2.
Proportional pulse pressure relates to cardiac index in stabilized acute heart failure patients.
Clin Exp Hypertens
; 40(7): 637-643, 2018.
Article
in English
| MEDLINE | ID: mdl-29265934
3.
PASylation technology improves recombinant interferon-ß1b solubility, stability, and biological activity.
Appl Microbiol Biotechnol
; 101(5): 1975-1987, 2017 Mar.
Article
in English
| MEDLINE | ID: mdl-27833991
4.
A randomized, double-blind, placebo-controlled, multicentre study to assess haemodynamic effects of serelaxin in patients with acute heart failure.
Eur Heart J
; 35(7): 431-41, 2014 Feb.
Article
in English
| MEDLINE | ID: mdl-24255129
5.
Electrocardiographic markers predict left ventricular wall motion improvement in patients with acute myocardial infarction receiving thrombolysis.
J Electrocardiol
; 44(2): 148-51, 2011.
Article
in English
| MEDLINE | ID: mdl-21163492
6.
A Phase 2a dose-escalation study of the safety, tolerability, pharmacokinetics and haemodynamic effects of BMS-986231 in hospitalized patients with heart failure with reduced ejection fraction.
Eur J Heart Fail
; 19(10): 1321-1332, 2017 10.
Article
in English
| MEDLINE | ID: mdl-28677877
7.
N-terminal region of Saccharomyces cerevisiae eRF3 is essential for the functioning of the eRF1/eRF3 complex beyond translation termination.
BMC Mol Biol
; 7: 34, 2006 Oct 11.
Article
in English
| MEDLINE | ID: mdl-17034622
Results
1 -
7
de 7
1
Next >
>>